Patrick M. Brunner

Patrick M. Brunner

Auto-generated profile, based on publicly available information

Patrick M. Brunner

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
HEHitokazu Esaki
Hitokazu Esaki
PBPatrick M. Brunner
Patrick M. Brunner
YRYael Renert-Yuval
Yael Renert-Yuval
TCTali Czarnowicki
Tali Czarnowicki
THThy Huynh
Thy Huynh
EGEmma Guttman-Yassky
Emma Guttman-Yassky

1 January 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PBPatrick M. Brunner
Patrick M. Brunner
JSJonathan Silverberg
Jonathan Silverberg
EGEmma Guttman-Yassky
Emma Guttman-Yassky
Amy PallerAmy Paller
Amy Paller
KKKenji Kabashima
Kenji Kabashima
ATAlain Taieb
Alain Taieb
Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections. Associations with cardiovascular, neuropsychiatric, and malignant diseases were increasingly reported, but confirmation of their link with atopic dermatitis requires longitudinal studies. Given the possibility of atopic dermatitis-related systemic immune activation, future investigations of new interventions should concurrently examine the impact on these comorbidities.

1 May 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
EGEmma Guttman-Yassky
Emma Guttman-Yassky
PBPatrick M. Brunner
Patrick M. Brunner
ANAvidan U. Neumann
Avidan U. Neumann
SKSaakshi Khattri
Saakshi Khattri
APAna B. Pavel
Ana B. Pavel
MLMark G. Lebwohl
Mark G. Lebwohl
Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function. Evaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD). We performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point. At 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections. The limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD. Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.

1 May 2019 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
PBPatrick M. Brunner
Patrick M. Brunner
EGEmma Guttman-Yassky
Emma Guttman-Yassky

1 November 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
TRThomas B. Rojahn
Thomas B. Rojahn
VVVera Vorstandlechner
Vera Vorstandlechner
TKThomas Krausgruber
Thomas Krausgruber
WBWolfgang M. Bauer
Wolfgang M. Bauer
NANatalia Alkon
Natalia Alkon
PBPatrick M. Brunner
Patrick M. Brunner

1 June 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PBPatrick M. Brunner
Patrick M. Brunner
AIAriel Israel
Ariel Israel
NZNing Zhang
Ning Zhang
ALAlexandra Leonard
Alexandra Leonard
HWHuei-Chi Wen
Huei-Chi Wen
EGEmma Guttman-Yassky
Emma Guttman-Yassky